Drugs / Chimeric antigen receptor T cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04650724 | Oct → Dec 2018 | plasma cell myeloma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT05705570 | Feb 2023 → May 2028 expected | B-cell chronic lymphocytic leukemia | Nelson Hamerschlak | Recruiting | No outcome recorded |
| Phase 1 | NCT05225363 | May 2022 → Nov 2028 expected | ovarian carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03291444 | May 2018 → Dec 2024 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03423992 | Mar 2018 → Jan 2023 | malignant glioma | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chimeric Antigen Receptor T-cells | “Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors” NCT04650724 ↗4“Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0” NCT05705570 ↗ |
| Known as | CAR-T | “Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0” NCT05705570 ↗ |
| Action | Deplete | “use the patient's own immune cells to clear cancer cells” NCT04650724 ↗ |
| Modality | Cell therapy | “CD19 CAR T-cell therapy” PMID 38712616 ↗ May 2024 |
| Route | Intravenous | “A single infusion of EphA2-redirected CAR T-cells was administrated intravenously” PMID 34235085 ↗ Jun 2021 |
| Target | CD19 | “There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and...” NCT03291444 ↗ |
| Target | CD22 | “There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and...” NCT03291444 ↗ |
| Target | CD33 | “There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and...” NCT03291444 ↗ |
| Target | CD34 | “There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and...” NCT03291444 ↗ |
| Target | CD38 | “There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and...” NCT03291444 ↗ |